TCL1A and ATM are co-expressed in chronic lymphocytic leukemia cells without deletion of 11q

被引:3
|
作者
Garding, Angela [1 ,2 ]
Bhattacharya, Nupur [1 ,3 ]
Haebe, Sarah [1 ]
Mueller, Frederike [4 ]
Weichenhan, Dieter [5 ]
Idler, Irina [1 ]
Ickstadt, Katja [4 ]
Stilgenbauer, Stephan [6 ]
Mertens, Daniel [1 ,6 ]
机构
[1] Univ Ulm, DKFZ Heidelberg, Cooperat Unit Mech Leukemogenesis, D-89069 Ulm, Germany
[2] Inst Mol Biol, Mainz, Germany
[3] Stanford Univ, Dept Pathol, Sch Med, Stanford, CA 94305 USA
[4] Tech Univ Dortmund, Dept Stat & Biometry, Dortmund, Germany
[5] DKFZ Heidelberg, Dept Epigen & Canc Risk Factors, Heidelberg, Germany
[6] Univ Ulm, Dept Internal Med 3, D-89069 Ulm, Germany
关键词
KINASE-ACTIVITY; B-CELLS; EXPRESSION; METHYLATION; ACTIVATION; REGULATOR; SIGNALS;
D O I
10.3324/haematol.2012.070623
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Chronic lymphocytic leukemia is characterized by the accumulation of B cells that are resistant to apoptosis. This resistance is induced by pro-survival stimuli from the microenvironment. TCL1 and ATM are central to the pathogenesis of the disease and associated with more aggressive disease. Their protein products have recently been shown to physically interact in leukemic cells and to impact on NF-kappa B signaling, which is a key regulator of apoptosis. In the present study we show that TCL1 and ATM are significantly co-expressed and up-regulated in malignant cells compared to non-malignant B cells, and that expression of TCL1 is partially deregulated by aberrant DNA-methylation. In addition, complex external stimuli induce essentially similar TCL1 and ATM time-course kinetics. In line with a coordinative regulation of NF-kappa B signaling by TCL1, its knockdown induced apoptosis in primary leukemia cells. These findings suggest that both genes functionally cooperate to modulate similar apoptosis-related cellular pathways.
引用
收藏
页码:269 / 273
页数:5
相关论文
共 50 条
  • [21] Clinical and Biological Impact of TP53 Alterations in Del(11q) Chronic Lymphocytic Leukemia
    Carretero, Claudia Perez
    Alamo, Miguel Quijada
    Hernandez-Sanchez, Maria
    Rodriguez, Ana E.
    Herrero, Ana B.
    Hernandez-Sanchez, Jesus M.
    Izquierdo, Marta Martin
    Gonzalez, Teresa
    Santos-Minguez, Sandra
    Miguel-Garcia, Cristina
    Rubio-Martinez, Araceli
    de Coca, Alfonso Garcia
    Davila, Julio
    Hernandez, Jose-Angel
    Benito, Rocio
    Ordonez, Jose Luis
    Hernandez-Rivas, Jesus Maria
    BLOOD, 2020, 136
  • [22] Analysis of single and complex 11q abnormalities in chronic lymphocytic leukemia: Correlation with clinical features.
    Garcia-Marco, JA
    Polo, N
    Perez-Aliaga, A
    de la Fuente, MS
    Fores, R
    Garcia-Vela, JA
    Fernandez, MN
    BLOOD, 1999, 94 (10) : 492A - 492A
  • [23] miR-34b/miR-34c: a regulator of TCL1 expression in 11q− chronic lymphocytic leukaemia?
    B Cardinaud
    C Moreilhon
    B Marcet
    K Robbe-Sermesant
    K LeBrigand
    B Mari
    V Eclache
    F Cymbalista
    S Raynaud
    P Barbry
    Leukemia, 2009, 23 : 2174 - 2177
  • [24] Low prevalence and independent prognostic role of del(11q) in Chinese patients with chronic lymphocytic leukemia
    Zou, Yi-Xin
    Tang, Han-Ning
    Zhang, Jing
    Tang, Xiao-Lu
    Qin, Shu-Chao
    Xia, Yi
    Zhu, Hua-Yuan
    Qiao, Chun
    Wang, Li
    Fan, Lei
    Xu, Wei
    Li, Jian-Yong
    Miao, Yi
    TRANSLATIONAL ONCOLOGY, 2021, 14 (10):
  • [25] DNA-PK hyperactivation occurs in deletion 11q chronic lymphocytic leukemia and is both a biomarker and therapeutic target for drug-resistant disease
    Sara E. F. Kost
    Ali Saleh
    Shek H. Yuan
    Bozena Kuzio
    Spencer B. Gibson
    Lin Yang
    Versha Banerji
    James B. Johnston
    Sachin Katyal
    Blood Cancer Journal, 13
  • [26] DNA-PK hyperactivation occurs in deletion 11q chronic lymphocytic leukemia and is both a biomarker and therapeutic target for drug-resistant disease
    Kost, Sara E. F.
    Saleh, Ali
    Yuan, Shek H.
    Kuzio, Bozena
    Gibson, Spencer B.
    Yang, Lin
    Banerji, Versha
    Johnston, James B.
    Katyal, Sachin
    BLOOD CANCER JOURNAL, 2023, 13 (01)
  • [27] Clinical Outcomes for Chronic Lymphocytic Leukemia (CLL) Patients with 11q Deletion in British Columbia (BC), Canada: Results of a Population-Based Cohort
    Goy, Jennifer
    Gillan, Tanya L.
    Steven, Huang J. T.
    Bruyere, Helene
    Hrynchak, Monica Anne
    Karsan, Aly
    Ramadan, Khaled
    Smith, Adam C.
    Toze, Cynthia L.
    Gerrie, Alina S.
    BLOOD, 2014, 124 (21)
  • [28] Cryptic deletion involving the ATM locus at 11q22.3∼q23.1 in B-cell chronic lymphocytic leukemia and related disorders
    Eclache, V
    Caulet-Maugendre, S
    Poirel, HA
    Djemai, M
    Robert, J
    Lejeune, F
    Raphaël, M
    CANCER GENETICS AND CYTOGENETICS, 2004, 152 (01) : 72 - 76
  • [29] Distinct gene expression profiling in chronic lymphocytic leukemia with 11q23 deletion
    Y Aalto
    W El-Rifai
    L Vilpo
    J Ollila
    B Nagy
    M Vihinen
    J Vilpo
    S Knuutila
    Leukemia, 2001, 15 : 1721 - 1728
  • [30] Distinct gene expression profiling in chronic lymphocytic leukemia with 11q23 deletion
    Aalto, Y
    El-Rifai, W
    Vilpo, L
    Ollila, J
    Nagy, B
    Vihinen, M
    Vilpo, J
    Knuutila, S
    LEUKEMIA, 2001, 15 (11) : 1721 - 1728